Table 1:
Variables | CBDEP group (n=19) | P-Value | Placebo group (n=17) | P-Value | Mean difference | 95% CI | P- Value | ||
---|---|---|---|---|---|---|---|---|---|
Baseline | 8 weeks | Baseline | 8 weeks | ||||||
Disease severity | |||||||||
Total UPDRS | 55.9±26.14 | 46.5±25.40 | 0.004* | 68.1±32.4 | 53.1±33.0 | <0.001* | 4.32 | −3.68 to 13.32 | 0.290 |
UPDRS part I | 8.58±6.04 | 5.47±3.53 | <0.001* | 13.88±7.62 | 8.52±8.01 | <0.001* | 1.1 | −1.16 to 3.36 | 0.340 |
UPDRS part II | 10±6.11 | 8.53±6.48 | 0.109 | 13±6.52 | 10.12±7.58 | 0.013* | 1.01 | −1.34 to 3.36 | 0.400 |
UPDRS part III | 34.78±16.19 | 29.68±16.28 | 0.020* | 38.29±19.30 | 31.41±17.81 | 0.005* | 1.28 | −3.86 to 6.41 | 0.626 |
UPDRS part IV | 2.57±3.77 | 2.8±2.69 | 0.478 | 2.88±4.38 | 3±3.75 | 0.673 | 0.092 | −0.61 to 0.79 | 0.796 |
Quality of life | |||||||||
EQ-5D-5L | 0.77±0.27 | 0.87±0.30 | 0.006* | 0.65±0.30 | 0.92±0.21 | <0.001* | −0.14 | −0.23 to−0.04 | 0.004* |
Functional performance | |||||||||
TUG (sec) | 14.16±6.17 | 13.28±3.86 | 0.337 | 13.90±5.73 | 12.65±3.40 | 0.133 | 0.49 | −1.08 to 2.06 | 0.537 |
FTSTS (sec) | 13.95±4.29 | 13.66±3.54 | 0.490 | 15.10±7.41 | 13.91±5.38 | 0.096 | 0.63 | −0.63 to 1.88 | 0.327 |
Gait velocity | |||||||||
(m/sec) | 1.08±0.23 | 1.13±0.21 | 0.107 | 1.07±0.25 | 1.18±0.23 | 0.043* | −0.06 | −0.17 to 0.06 | 0.322 |
HADS score | |||||||||
Anxiety score | 3.73±2.66 | 2.94±2.12 | 0.067 | 5.05±2.86 | 4.76±3.41 | 0.822 | −0.82 | −1.97 to 0.33 | 0.160 |
Depression score | 3.157±2.75 | 2.05±1.71 | 0.015* | 5.11±3.14 | 3.23±3.13 | 0.066 | −0.37 | −1.73 to 0.98 | 0.590 |
Data are presented as mean±standard deviation, *P<0.05, CBDEP, cannabidiol-enriched cannabis extraction product; CI, confidence interval; UPDRS, Unified Parkinson’s Disease Rating Scale; TUG, Timed Up and Go; FTSTS, Five Times Sit to Stand; HADS, Hospital Anxiety and Depression Scale.